Ipsen delivers strong sales growth of 22.6% for the third quarter of 2017

Paris (France), 26 October 2017 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced sales for the third quarter of 2017.

Financial highlights

  • Q3 2017 Group sales growth of 22.6%1 driven by Specialty Care sales growth of 26.5%1 reflecting continued Somatuline® momentum and increasing contribution of new products Cabometyx® and Onivyde®, and solid Consumer Healthcare sales growth of 5.0%1
  • YTD Group sales growth of 20.1%1 fueled by Specialty Care sales growth of 24.3%1 and Consumer Healthcare back to growth at 2.5%1
  • Full Year 2017 guidance confirmed: Specialty Care sales growth greater than 24%1, Consumer Healthcare back to growth1 and a Core Operating Income margin greater than 25% of net sales

Recent pipeline highlights

  • Approval of Somatuline® by FDA2 for the treatment of carcinoid syndrome in the U.S.
  • Approval of Xermelo® by EMA2 for the treatment of carcinoid syndrome diarrhea in combination with SSA2 therapy
  • Validation by EMA2 of the application of Cabometyx® for the addition of a new indication in first-line treatment of advanced renal cell carcinoma (RCC)
  • Phase 3 CELESTIAL trial of cabozantinib meets primary endpoint of overall survival in patients with advanced hepatocellular carcinoma

 Key figures

Third quarter and nine months 2017 unaudited IFRS consolidated sales

David Meek, Chief Executive Officer of Ipsen stated: “The excellent performance in the third quarter reflects the continued execution against our 2017 objectives with an accelerated momentum of our Specialty Care business. We achieved several important pipeline milestones during the quarter, notably in Oncology, further strengthening our leadership position in the neuroendocrine tumor market and increasing the potential value of the Cabometyx franchise. We remain focused on the launch execution of our new products and building an innovative and sustainable pipeline.”

For further information on comparison of Consolidated Sales for the Third Quarter and First Nine Months of 2017 and 2016; and major developments

1/ Year-on-year growth excluding foreign exchange impacts

2/ Food and Drug Administration (FDA), European Medicines Agency (EMA), Somatostatin Analog (SSA)

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2021